Category: Press Release

Download PDF BOSTON, October 20, 2026 (PR Newswire) — AVEO Oncology, an LG Chem company, (AVEO) announced today that an abstract was accepted for presentation at the upcoming 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain this October 23-27. The poster will summarize results from a Phase 1b study designed to test

Download PDF BOSTON, June 30, 2026 /PRNewswire/ — AVEO Pharmaceuticals, Inc., an LG Chem company, (“AVEO”), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, announced today that, as part of a comprehensive succession planning process, Michael P. Bailey will step down as President and Chief Executive Officer effective June 30, 2026, following

Download PDF BOSTON, May 5, 2026 (PR Newswire) — AVEO Oncology, an LG Chem company (“AVEO”), announced today that two abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2026 annual meeting this May 29-June 2, 2026, in Chicago, IL.   Presentation Details Title: Final analysis of the TiNivo-2 phase

Download PDF BOSTON, February 18, 2026 (PR NEWSWIRE) — AVEO Oncology, an LG Chem company, (AVEO) announced today that the 20mg/kg dose of ficlatuzumab was selected for the combination arm of the Phase 3 registrational FIERCE-HN clinical trial. This dose selection decision follows the recommendation of the Independent Data Monitoring Committee and alignment with the

Download PDF BOSTON, January 14, 2026 (PR NEWSWIRE) — AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and venetoclax in patients that are 60 years of age or older with untreated acute myeloid leukemia

Download PDF BOSTON, November 4, 2025 (PR Newswire) — AVEO Oncology, an LG Chem company (AVEO), and HiberCell, Inc. (HiberCell) announced today that the companies have entered into an exclusive development and option agreement to develop HiberCell’s first-in-human human protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitor, HC-5404, alone and in combination with AVEO’s potent

Download PDF BOSTON, June 3, 2025 (PR Newswire) – AVEO Oncology, an LG Chem company (“AVEO”), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, presented three posters during the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago, IL, including one exploratory sub-analysis for tivozanib and two trials

Download PDF BOSTON, April 28, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, announced today that three abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2025 annual meeting this May 30-June 3, 2025, in

Download PDF – Cumulative data of three Phase 3 studies demonstrate greater exposure of tivozanib is associated with increased clinical benefit ––  Patient Reported Outcomes were numerically better for patients receiving tivozanib in a second line setting versus third line – BOSTON, Feb. 18, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is

Download PDF BOSTON, Feb. 12, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, announced today two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) 2025 meeting this February 13-15, 2025, in San